Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Oncology

What Does MRD Negative Mean in Acute Myeloid Leukemia?

At a Glance

An MRD negative result in acute myeloid leukemia means highly sensitive lab tests cannot detect any remaining leukemia cells in your blood or bone marrow. While not a guarantee of a cure, it indicates a deep remission and is the best predictor for long-term survival.

In this answer

3 sections

01

What is Measurable Residual Disease?

02

How Sensitive Are MRD Tests?

03

What an MRD Negative Result Means for Your Future

If your test results say you are MRD negative, it means that highly sensitive medical tests could not find any remaining leukemia cells in your bone marrow or blood. MRD stands for Measurable Residual Disease (sometimes called Minimal Residual Disease). Reaching an MRD negative status is an incredibly encouraging milestone, as it is currently the best predictor for long-term survival and staying in remission [1][2].

You might be wondering: does this mean I am cured? Doctors prefer the term “remission” because an MRD negative result means the disease is undetectable by our best tests, rather than a guarantee that it is 100% gone forever. Still, this result means your treatment has worked exceptionally well and gives you the best possible chance for a lasting recovery [1].

What is Measurable Residual Disease?

Historically, doctors determined if a patient was in remission by looking at a bone marrow sample under a standard microscope. If fewer than 5% of the cells were leukemia cells (called blasts), the patient was considered to be in “morphological complete remission” [1][3].

However, standard microscopes cannot see everything. Even when you are in a complete remission visually, a tiny number of leukemia cells may still be hiding [1][4]. These hidden cells are your Measurable Residual Disease. Because these lingering cells are what can eventually cause a relapse, finding out whether they are present is a critical part of your acute myeloid leukemia (AML) treatment journey [1][5].

How Sensitive Are MRD Tests?

To find these subclinical (hidden) leukemia cells, doctors use highly advanced, sensitive laboratory techniques [4][6]. The three most common methods are:

  • Multiparameter Flow Cytometry (MFC): This test scans for abnormal proteins on the surface of cells [7][8].
  • Polymerase Chain Reaction (PCR): This is a highly sensitive molecular test used to detect specific, known genetic targets in your leukemia (like an NPM1 mutation) [4].
  • Next-Generation Sequencing (NGS): This test looks deep inside the cells’ DNA to find a broader range of specific genetic mutations (like IDH1/2 or FLT3 in AML) that were present when you were first diagnosed [7][9].

These tests are remarkably powerful. Depending on the specific technique, they can search through hundreds of thousands or even millions of healthy cells to find a single leukemia cell.

  • Standard flow cytometry can often detect 1 leukemia cell among 10,000 to 100,000 normal cells [10][11].
  • High-sensitivity molecular tests (like PCR and NGS) can sometimes detect 1 leukemia cell among 100,000 to 1,000,000 normal cells [10][6].

If an MRD test comes back negative, it means that within that massive sample of cells, not a single leukemia cell could be detected by the test [1][4].

What an MRD Negative Result Means for Your Future

Achieving an MRD negative status provides powerful information about your future health:

  • Better Predictor of Survival: Research has shown that an MRD negative status is a vastly superior predictor of long-term survival and relapse risk compared to traditional morphological remission [1][2][5].
  • Guiding Future Treatments: Your care team will use your MRD status to tailor your treatment plan [12][13]. If you are MRD negative, it confirms that your current treatment is working as intended.
  • Stem Cell Transplant Outcomes: For patients preparing for an allogeneic stem cell transplant, achieving MRD negativity beforehand is linked to significantly better survival outcomes after the transplant [14][15][16].

What’s Next: Monitoring Your Remission

Because AML can sometimes return, your care team will continue to monitor your MRD status at key points in your treatment—such as after induction chemotherapy, after consolidation, and at regular intervals during follow-up [17][18].

You will likely have bone marrow biopsies or specialized blood tests scheduled periodically during your first few years of remission. An MRD negative result confirms that the volume of disease has been reduced to an undetectable level, giving you an excellent foundation moving forward.

Common questions in this guide

Does an MRD negative result mean my leukemia is cured?
An MRD negative result means highly sensitive tests cannot detect remaining leukemia cells, placing you in a deep remission. Because a microscopic number of cells can sometimes hide and cause a relapse later, doctors prefer the term remission rather than cure and will continue to monitor you.
How do doctors test for measurable residual disease in AML?
Doctors use highly advanced laboratory techniques on blood or bone marrow samples, such as multiparameter flow cytometry, PCR, or next-generation sequencing (NGS). Depending on the method, these tests can find a single leukemia cell hidden among up to a million healthy cells.
How often will my MRD status be checked?
Your care team will typically check your MRD status at key milestones, such as after induction chemotherapy and consolidation therapy. During your first few years of remission, you will likely have regular bone marrow biopsies or blood tests to monitor for any returning disease.
How does an MRD negative result affect my treatment plan or stem cell transplant?
Your MRD status provides crucial information that helps your doctor tailor your treatment plan. If you are preparing for a stem cell transplant, achieving an MRD negative status beforehand is linked to significantly better survival and recovery outcomes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific method (flow cytometry, PCR, or NGS) was used to check my MRD status?
  2. 2.How sensitive was the test used, and what is its limit of detection?
  3. 3.How frequently will we re-check my MRD status moving forward?
  4. 4.Do my original genetic mutations (such as NPM1 or FLT3) change how we monitor my MRD?
  5. 5.Since my test is MRD negative, does this change our plans for a stem cell transplant or maintenance therapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can You Be Diagnosed with AML with Less Than 20% Blasts?Does AML Chemotherapy Cause Long-Term Heart Problems?Does the Treatment Center Matter for AML Survival?How Do FLT3 and NPM1 Mutations Affect AML?How Do Doctors Assess Fitness for AML Chemotherapy?How is Venetoclax Given for Acute Myeloid Leukemia?How Long Does Chemo Brain Last After AML Treatment?What Are the ELN Risk Categories in AML?What Are AML Induction & Consolidation Therapies?What Are AML Skin and Gum Symptoms? | Inciteful MedWhat Conditions Mimic Acute Myeloid Leukemia?What is cGVHD After an AML Stem Cell Transplant?What Is a Day 14 Bone Marrow Biopsy in AML Treatment?

References

References (18)
  1. 1

    Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy.

    Appelbaum FR

    Best practice & research. Clinical haematology 2018; (31(4)):405-409 doi:10.1016/j.beha.2018.09.009.

    PMID: 30466757
  2. 2

    Recurrence of minimal residual disease in acute myeloid leukemia: a window of opportunity for intervention.

    Bankar A

    Haematologica 2025; (110(12)):2881-2883 doi:10.3324/haematol.2025.288227.

    PMID: 40820796
  3. 3

    Measurable residual disease testing for personalized treatment of acute myeloid leukemia.

    Ehinger M, Pettersson L

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2019; (127(5)):337-351 doi:10.1111/apm.12926.

    PMID: 30919505
  4. 4

    How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy.

    Heuser M, Mina A, Stein EM, Altman JK

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2019; (39()):411-420 doi:10.1200/EDBK_238687.

    PMID: 31099617
  5. 5

    Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis.

    Short NJ, Fu C, Berry DA, et al.

    Leukemia 2022; (36(12)):2817-2826 doi:10.1038/s41375-022-01692-0.

    PMID: 36261575
  6. 6

    How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?

    Short NJ, Ravandi F

    Haematologica 2019; (104(8)):1532-1541 doi:10.3324/haematol.2018.208454.

    PMID: 31273094
  7. 7

    Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions.

    Moritz J, Schwab A, Reinisch A, et al.

    Biomedicines 2024; (12(3)) doi:10.3390/biomedicines12030599.

    PMID: 38540210
  8. 8

    28-color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal/measurable residual disease.

    Gao Q, Chan A, Zhang J, et al.

    Cytometry. Part B, Clinical cytometry 2025; (108(3)):198-211 doi:10.1002/cyto.b.22233.

    PMID: 40134341
  9. 9

    Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia.

    Butler JT, Yashar WM, Swords R

    American journal of hematology 2025; (100(4)):638-651 doi:10.1002/ajh.27586.

    PMID: 39777414
  10. 10

    Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.

    Delsing Malmberg E, Rehammar A, Pereira MB, et al.

    The Journal of molecular diagnostics : JMD 2019; (21(1)):149-162 doi:10.1016/j.jmoldx.2018.08.004.

    PMID: 30273780
  11. 11

    Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia.

    Boudry A, Goursaud L, Lebon D, et al.

    British journal of haematology 2025; (207(5)):1953-1961 doi:10.1111/bjh.70135.

    PMID: 40903763
  12. 12

    Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.

    Oran B, Jorgensen JL, Marin D, et al.

    Haematologica 2017; (102(1)):110-117 doi:10.3324/haematol.2016.144253.

    PMID: 27540139
  13. 13

    Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission.

    Jiang L, Cheng J, Sun J, et al.

    British journal of haematology 2025; (206(1)):250-262 doi:10.1111/bjh.19917.

    PMID: 39578220
  14. 14

    Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.

    Kim HJ, Kim Y, Kang D, et al.

    Blood cancer journal 2021; (11(6)):109 doi:10.1038/s41408-021-00500-9.

    PMID: 34088902
  15. 15

    Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.

    Li SQ, Yu CZ, Xu LP, et al.

    Bone marrow transplantation 2025; (60(3)):277-285 doi:10.1038/s41409-024-02466-1.

    PMID: 39550501
  16. 16

    Excellent Outcomes of Hematopoietic Stem Cell Transplant for Pediatric High Risk and Relapsed Acute Myeloid Leukemia-A Decade Long Experience From Developing Nation.

    Arora S, Danewa AS, Chakraborty S, et al.

    Journal of pediatric hematology/oncology 2026; (48(1)):18-23 doi:10.1097/MPH.0000000000003151.

    PMID: 41359907
  17. 17

    Consensus on MRD in AML?

    Paietta E

    Blood 2018; (131(12)):1265-1266 doi:10.1182/blood-2018-01-828145.

    PMID: 29567752
  18. 18

    The emerging role of measurable residual disease detection in AML in morphologic remission.

    Buccisano F, Maurillo L, Schuurhuis GJ, et al.

    Seminars in hematology 2019; (56(2)):125-130 doi:10.1053/j.seminhematol.2018.09.001.

    PMID: 30926088

This page explains measurable residual disease (MRD) test results for educational purposes. Always consult your hematologist or oncologist to interpret your specific AML lab results and discuss your ongoing treatment plan.

Get notified when new evidence is published on Acute myeloid leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.